SK Biopharmaceuticals Co. on Thursday reported its first-quarter net income of 9.7 billion won (US$7.1 million), turning from a loss of 2.4 billion won a year earlier. Operating income for the January-March period was 10.3 billion, compared with a loss of 22.7 billion won a year ago, the company said in a regulatory filing. Sales rose 87.5 percent to 114 billion won. Source: Yonhap News Agency